Technical Analysis for FGEN - FibroGen, Inc

Grade Last Price % Change Price Change
F 0.35 0.00% 0.00
FGEN closed unchanged on Wednesday, November 20, 2024, on approximately normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Calm After Storm Range Contraction 3.73%
Narrow Range Bar Range Contraction 3.73%
Inside Day Range Contraction 3.73%
Gapped Up Strength 3.73%
Fell Below 50 DMA Bearish 4.57%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago
10 DMA Support about 21 hours ago
Down 3% about 21 hours ago
Down 2 % about 22 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

FibroGen, Inc Description

FibroGen, Inc. operates as a research-based biopharmaceutical company in the United States. The company focuses on the discovery, development, and commercialization of therapeutic agents to treat serious unmet medical needs. The company develops roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019, a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. It also focuses on use of the proprietary type III recombinant human collagens in its biosynthetic corneal implant product candidate, FG-5200 for the treatment of corneal blindness. The company was incorporated in 1993 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Monoclonal Antibody Kidney Disease Pancreatic Cancer Anemia Idiopathic Pulmonary Fibrosis Chronic Kidney Disease Pulmonary Fibrosis Blindness Cornea Collagen Liver Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Hypoxia Inducible Factors

Is FGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.93
52 Week Low 0.18
Average Volume 1,249,132
200-Day Moving Average 1.03
50-Day Moving Average 0.36
20-Day Moving Average 0.33
10-Day Moving Average 0.34
Average True Range 0.04
RSI (14) 51.22
ADX 24.85
+DI 14.08
-DI 25.43
Chandelier Exit (Long, 3 ATRs) 0.29
Chandelier Exit (Short, 3 ATRs) 0.31
Upper Bollinger Bands 0.37
Lower Bollinger Band 0.28
Percent B (%b) 0.75
BandWidth 27.48
MACD Line 0.00
MACD Signal Line -0.01
MACD Histogram 0.0056
Fundamentals Value
Market Cap 34.42 Million
Num Shares 98.3 Million
EPS -3.06
Price-to-Earnings (P/E) Ratio -0.11
Price-to-Sales 1.71
Price-to-Book 53.83
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.39
Resistance 3 (R3) 0.39 0.37 0.38
Resistance 2 (R2) 0.37 0.36 0.37 0.38
Resistance 1 (R1) 0.36 0.36 0.36 0.36 0.38
Pivot Point 0.35 0.35 0.35 0.35 0.35
Support 1 (S1) 0.34 0.34 0.33 0.34 0.32
Support 2 (S2) 0.32 0.33 0.32 0.32
Support 3 (S3) 0.31 0.32 0.32
Support 4 (S4) 0.31